超声引导射频消融治疗三发性甲状旁腺功能亢进的前瞻性研究
该前瞻性研究纳入38例三发性甲状旁腺功能亢进患者(36例肾衰竭,2例肾移植后),评估超声引导射频消融的疗效与安全性。36例肾衰竭患者术后48个月iPTH由基线1284.9 pg/mL降至261.1 pg/mL(P=0.012),持续性甲旁亢发生率4.0%(1/25),永久性低钙血症发生率10.5%(4/38),骨痛、关节痛、皮肤瘙痒严重程度评分改善(P<0.05)。作者结论认为超声引导射频消融是安全有效的替代手术方法。
要点
- 射频消融后48个月iPTH由基线1284.9 pg/mL降至261.1 pg/mL(P=0.012)。
- 持续性甲旁亢(iPTH>585.0 pg/mL持续6个月)发生率4.0%(1/25)。
- 永久性低钙血症发生率10.5%(4/38),其余并发症6个月内自行缓解。
核心结论
- 超声引导射频消融治疗三发性甲状旁腺功能亢进有效且安全,可作为手术的替代方法,并改善甲旁亢相关临床症状。
研究设计与样本
- 前瞻性研究,2017年9月至2022年1月行超声引导射频消融的三发性甲旁亢患者,最终纳入38例(36例肾衰竭、2例肾移植后;男:女=17:21;中位年龄54.5岁),36例肾衰竭患者随访21.5±19.0个月,监测血清iPTH等实验室指标至术后48个月。
诊断标准与关键数值
- 持续性甲旁亢定义为治疗后iPTH维持>585.0 pg/mL达6个月,发生率4.0%(1/25);复发性甲旁亢定义为6个月后iPTH>585.0 pg/mL,术后6个月发生率4.0%(1/25)、术后4年发生率0.0%(0/9)。
临床应用与阅片要点
- 作者结论认为超声引导射频消融是三发性甲旁亢安全有效的替代手术方法;36例肾衰竭患者iPTH由基线1284.9 pg/mL降至术后48个月261.1 pg/mL(P=0.012),骨痛、关节痛、皮肤瘙痒严重程度评分改善(P<0.05),总体症状恢复率58.8%(10/17)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To prospectively evaluate the outcomes of ultrasound (US)-guided radiofrequency ablation (RFA) in tertiary hyperparathyroidism (THPT).
MATERIALS AND METHODS: Patients with THPT underwent RFA between September 2017 and January 2022. Laboratory parameters, including serum intact parathyroid hormone (iPTH) levels, were monitored for 48 months after RFA and compared with the levels at baseline. Complications related to RFA and changes in hyperparathyroidism-related clinical symptoms were recorded before and after RFA.
RESULTS: A total of 42 patients with THPT were recruited for this study. Ultimately, 36 patients with renal failure and 2 patients who underwent successful renal transplantation (male:female, 17:21; median age, 54.5 years) were enrolled. The follow-up time was 21.5 ± 19.0 months in the 36 patients with renal failure. In these 36 patients, iPTH levels were significantly decreased to 261.1 pg/mL at 48 months compared with the baseline value of 1284.9 pg/mL (P = 0.012). Persistent hyperparathyroidism, defined as iPTH levels maintained at > 585.0 pg/mL for 6 months after treatment, occurred in 4.0% of patients (1/25). Recurrent hyperparathyroidism, defined as iPTH levels > 585.0 pg/mL after 6 months, were 4.0% (1/25) and 0.0% (0/9) at 6 months and 4 years after treatment, respectively. In two patients with THPT after successful renal transplantation, iPTH decreased from the baseline value of 242.5 and 115.9 pg/mL to 171.0 and 62.0 pg/mL at 6 months after treatment. All complications resolved within 6 months of ablation without medical intervention, except in 10.5% (4/38) patients with permanent hypocalcemia. The overall symptom recovery rate was 58.8% (10/17). The severity scores for bone pain, arthralgia, and itchy skin associated with hyperparathyroidism improved after treatment (P < 0.05).
CONCLUSION: US-guided RFA is an effective and safe alternative to surgery in the treatment of patients with TPTH and improves hyperparathyroidism-related clinical symptoms.
引用
- Deng E, Jiang T, Chai H, et al. Ultrasound-Guided Radiofrequency Ablation in Tertiary Hyperparathyroidism: A Prospective Study. Korean J Radiol. 2024. PMID: 38413113. doi:10.3348/kjr.2023.0176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。